Guiding recombinant antivenom development by omics technologies

Area of Science:

• * Explores novel strategies in toxicology and immunology for antivenom development.
• * Focuses on the intersection of proteomics, bioinformatics, and clinical toxicology.

Background:

• * Traditional antivenom production faces challenges in efficacy and specificity.
• * Animal envenomings remain a significant global health concern, necessitating improved treatments.

Purpose of the Study:

• * To review and discuss emerging approaches for novel antivenom development.
• * To highlight the role of omics technologies in understanding venom composition and guiding antivenom design.
• * To examine methods for evaluating antivenom specificity and cross-reactivity.

Main Methods:

• * Review of innovative immunization strategies and small molecule inhibitors.
• * Discussion of endogenous proteins and recombinant monoclonal antibodies.
• * Application of omics technologies: venomics, antivenomics, and toxicovenomics.
• * Assessment of antivenom specificity using antivenomics and peptide microarrays.

Main Results:

• * Innovative strategies show promise for developing targeted and effective antivenoms.
• * Omics technologies provide critical insights into venom complexity and toxin relevance.
• * Antivenomics and peptide microarrays are valuable tools for specificity assessment.

Conclusions:

• * A comprehensive understanding of venom composition is essential for next-generation antivenom design.
• * The integration of omics technologies and advanced biotechnological approaches is key to overcoming current limitations.
• * Future antivenom development will benefit from precise toxin identification and robust efficacy/specificity testing.